Eisai Co Ltd (ESALF) 38.2000 $ESALF
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Depression - Pipeline Review, H1 2014: 55 Companies and 96 Drugs Profiled
M2 - Thu May 08, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2szh97/depression) has announced the addition of the "Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AB Science - Acetylon Pharmaceuticals, Inc. - Ache Laboratorios Farmaceuticos S/A - Acino Pharma AG - Addex Therapeutics - Affectis Pharmaceuticals AG - Allergan, Inc. - Anavex Life Sciences Corp. - Angelini Group - Angita B.V. - Aphios Corporation - AstraZeneca PLC - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - BioCrea GmbH - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Clera Inc. - Concert Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dart NeuroScience LLC - Domain Therapeutics SA - Eisai Co., Ltd. - Eli Lilly and Company - FAES Farma SA - Heptares Therapeutics Ltd. - Hydra Biosciences, Inc. - Impax Laboratories, Inc. - Indus Biotech Private Limited - Intra-Cellular Therapies, Inc. and many more Drug Profiles: - trazodone hydrochloride - quetiapine fumarate ER - Triple Reuptake Inhibitors - verucerfont - masitinib - nefiracetam - epoetin alfa - PH-10-A - CLR-3001 - Neurokinin-1 Receptor Antagonists For Depression - progesterone - SRX-251 - SRX-246 - ITI-007 - RGH-618 - fludrocortisone - BLI-1005 - WF-516 - Projectx-1120 - TS-111 - IPX-237 - SPN-809 - ANAVEX-1-41 - F-98214-TA - Xantol - E-2508 - NNI-351 - INDUS-860 - NW-3509 - SKL-PSY and many more For more information visit http://www.researchandmarkets.com/research/2szh97/depression
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
Recurrent Malignant Glioma linical Trials Review - H1 2014 Edition
M2 - Thu May 01, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2n5m9j/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Insys Therapeutics, Inc. - Merck & Co., Inc. - Eisai Co., Ltd. - TransMolecular, Inc. - Eli Lilly and Company - to-BBB technologies BV - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Direct Therapeutics, Inc. - Amgen Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - Northwestern University - UCLA's Jonsson Comprehensive Cancer Center - Sidney Kimmel Comprehensive Cancer Center - University of Colorado - Wake Forest University For more information visit http://www.researchandmarkets.com/research/2n5m9j/recurrent
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Global Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kxfhtk/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Glioblastoma Multiforme (GBM). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Merck & Co., Inc. - AstraZeneca PLC - Eli Lilly and Company - Eisai Co., Ltd. - Medicenna Therapeutics, Inc - E. Merck KG - Bristol-Myers Squibb Company - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Duke University - Massachusetts General Hospital - European Organization for Research and Treatment of Cancer - Rigshospitalet - Cedars-Sinai Medical Center - Case Comprehensive Cancer Center - University of Zurich For more information visit http://www.researchandmarkets.com/research/kxfhtk/recurrent
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Depression - Pipeline Review, H1 2014: 55 Companies and 96 Drugs Profiled
M2 - Thu May 08, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2szh97/depression) has announced the addition of the "Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AB Science - Acetylon Pharmaceuticals, Inc. - Ache Laboratorios Farmaceuticos S/A - Acino Pharma AG - Addex Therapeutics - Affectis Pharmaceuticals AG - Allergan, Inc. - Anavex Life Sciences Corp. - Angelini Group - Angita B.V. - Aphios Corporation - AstraZeneca PLC - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - BioCrea GmbH - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Clera Inc. - Concert Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dart NeuroScience LLC - Domain Therapeutics SA - Eisai Co., Ltd. - Eli Lilly and Company - FAES Farma SA - Heptares Therapeutics Ltd. - Hydra Biosciences, Inc. - Impax Laboratories, Inc. - Indus Biotech Private Limited - Intra-Cellular Therapies, Inc. and many more Drug Profiles: - trazodone hydrochloride - quetiapine fumarate ER - Triple Reuptake Inhibitors - verucerfont - masitinib - nefiracetam - epoetin alfa - PH-10-A - CLR-3001 - Neurokinin-1 Receptor Antagonists For Depression - progesterone - SRX-251 - SRX-246 - ITI-007 - RGH-618 - fludrocortisone - BLI-1005 - WF-516 - Projectx-1120 - TS-111 - IPX-237 - SPN-809 - ANAVEX-1-41 - F-98214-TA - Xantol - E-2508 - NNI-351 - INDUS-860 - NW-3509 - SKL-PSY and many more For more information visit http://www.researchandmarkets.com/research/2szh97/depression
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
Recurrent Malignant Glioma linical Trials Review - H1 2014 Edition
M2 - Thu May 01, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2n5m9j/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Insys Therapeutics, Inc. - Merck & Co., Inc. - Eisai Co., Ltd. - TransMolecular, Inc. - Eli Lilly and Company - to-BBB technologies BV - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Direct Therapeutics, Inc. - Amgen Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - Northwestern University - UCLA's Jonsson Comprehensive Cancer Center - Sidney Kimmel Comprehensive Cancer Center - University of Colorado - Wake Forest University For more information visit http://www.researchandmarkets.com/research/2n5m9j/recurrent
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Global Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kxfhtk/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Glioblastoma Multiforme (GBM). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Merck & Co., Inc. - AstraZeneca PLC - Eli Lilly and Company - Eisai Co., Ltd. - Medicenna Therapeutics, Inc - E. Merck KG - Bristol-Myers Squibb Company - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Duke University - Massachusetts General Hospital - European Organization for Research and Treatment of Cancer - Rigshospitalet - Cedars-Sinai Medical Center - Case Comprehensive Cancer Center - University of Zurich For more information visit http://www.researchandmarkets.com/research/kxfhtk/recurrent
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
